| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacy | 44 / 52 | 16th | Q4 |
| Surgery | 538 / 597 | 9th | Q4 |
| Oncology | 398 / 428 | 7th | Q4 |
Compare journals
Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
P.A. Herzen Journal of Oncology
P.A. Herzen Journal of Oncology is Scopus-indexed (Q4, CiteScore 0.3). Published by Media Sphera Publishing Group.
Checked against the index lists dated .
ISSN 2305-218XVerify ISSN ↗2309-4745Verify ISSN ↗
Publisher: Media Sphera Publishing Group
Cost to publish: No APC data — check the publisher
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Quick answers
Is P.A. Herzen Journal of Oncology indexed in Scopus?
Yes — actively indexed in Scopus, coverage 2012–present, best quartile Q4, CiteScore 0.3.
What quartile is P.A. Herzen Journal of Oncology in Scopus?
P.A. Herzen Journal of Oncology is Q4 in Pharmacy (rank 44 of 52), Q4 in Surgery (rank 538 of 597) and Q4 in Oncology (rank 398 of 428), by CiteScore 2025.
What is the impact factor of P.A. Herzen Journal of Oncology?
P.A. Herzen Journal of Oncology is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 0.3, quartile Q4, 16th percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.118, quartile Q4, with an H-index of 8.
Who publishes P.A. Herzen Journal of Oncology and what is its ISSN?
P.A. Herzen Journal of Oncology is published by Media Sphera Publishing Group. Its print ISSN is 2305-218X and its online ISSN is 2309-4745.
Is P.A. Herzen Journal of Oncology in Web of Science?
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Is P.A. Herzen Journal of Oncology open access?
No — it is not registered as an open-access journal in DOAJ or Scopus.
How well cited is P.A. Herzen Journal of Oncology? — open metrics via OpenAlex
P.A. Herzen Journal of Oncology has an h-index of 11 and a 2-year mean of 0.24 citations per paper (OpenAlex). Its Scopus CiteScore is 0.3, quartile Q4. On 2-year citations it ranks #35 of 50 Scopus journals in Pharmacy.
P.A. Herzen Journal of Oncology published 94 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
Who publishes in P.A. Herzen Journal of Oncology? — latest 92 articles, 2025–2026
In its latest 92 research articles (2025–2026), authors are most often from Russia (92.4%), Belarus (4.3%) and Azerbaijan (1.1%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Are there integrity warnings for P.A. Herzen Journal of Oncology? — indicators, not proof of misconduct
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
- Scopus statusActive
- Retracted papers None recorded
- Problematic Paper Screener flags None flagged
- Author concentration92.4% of recent authorship from Russia
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Official sources & links
Community experience: reader comments on this journal
Related journals
8 journalsIndex data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.